Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04923776 · ClinicalTrials.gov registry record · Phase 2
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
A Phase 2 study, sponsored by Brian Henick, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04923776 is a Phase 2 study that was terminated before completion, run by Brian Henick, MD. The registered enrollment target is 2 participants.
The verdict
NCT04923776, a Phase 2 study, was terminated before completion, sponsored by Brian Henick, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy including drugs called carboplatin and etoposide, that is combined with a type of immunotherapy called atezolizumab. However, patients with liver involvement of their ES-SCLC don't respond as well to this treatment. The study aims to answer whether adding radiation directed at liver metastases can improve responses to standard chemo-immunotherapy in this patient population. All study participants will get the same study intervention, which will be chemo-immunotherapy and radiation therapy.
Interventions
- DRUG Carboplatin
- DRUG Atezolizumab
- DRUG Etoposide
- RADIATION Stereotactic Body Radiation Therapy (SBRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04923776
The ClinicalTrials.gov registry entry for NCT04923776 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brian Henick, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT04923776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04923776 about?
NCT04923776 is a clinical study titled "Liver Directed RT + Chemo-immunotherapy for ES-SCLC". The purpose of this study is to evaluate whether radiation treatment directed at liver metastases can be safely added to standard of care treatment for extensive stage small cell lung cancer (ES-SCLC). The current standard treatment for people who have ES-SCLC is chemotherapy including drugs called ...
What is the current status of trial NCT04923776?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-09-20. Estimated completion is 2023-12-23.
What interventions are being tested in trial NCT04923776?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Etoposide (DRUG), Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT04923776?
This trial is sponsored by Brian Henick, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.